NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference
November 23 2009 - 4:30PM
PR Newswire (US)
SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
products for minimally disruptive surgical treatments for the
spine, announced today that Alex Lukianov, Chairman and Chief
Executive Officer, and Michael J. Lambert, Executive Vice President
and Chief Financial Officer, are scheduled to present at the 21st
Annual Piper Jaffray Health Care Conference at the New York Palace
in New York, New York, on Wednesday, December 2, 2009, at 10:00
a.m. ET. Mr. Lukianov and Mr. Lambert are also scheduled to present
at the J.P. Morgan SMid Cap Conference at the J.P. Morgan
Conference Center at 383 Madison Avenue in New York, New York, on
Thursday, December 3, 2009, at 1:30 p.m. ET. A live webcast of both
presentations will be available online from the investor relations
page of the Company's corporate website at
http://www.nuvasive.com/. After the live webcast, the presentations
will remain available on the website for 30 days. About NuVasive
NuVasive is a medical device company focused on the design,
development, and marketing of products for the surgical treatment
of spine disorders. The Company's product portfolio is focused
primarily on the $4.6 billion U.S. spine implant market.
Additionally, the Company has expanded into the $1.5 billion global
biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum
Access Surgery, or MAS® platform. The MAS platform combines four
categories of products that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and
safe, easy reproducibility for the surgeon: NeuroVision®, a
proprietary software-driven nerve avoidance system; MaXcess®, a
unique split-blade retractor system; a wide variety of specialized
implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily
living much faster than conventional approaches. Having redefined
spine surgery with the MAS platform's lateral approach, known as
eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an
entire spine franchise. With nearly 50 products today spanning
lumbar, thoracic and cervical applications, the Company will
continue to expand and evolve its offering predicated on its
R&D focus and dedication to outstanding service levels
supported by a culture of Absolute Responsiveness®. NuVasive
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties that could cause
actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or
clearance for NuVasive's products or devices, including risks that
such process could be significantly delayed; the possibility that
the FDA may require significant changes to NuVasive's products or
clinical studies; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk
that competitors may develop superior products or may have a
greater market position enabling more successful commercialization;
the risk that additional clinical data may call into question the
benefits of NuVasive's products to patients, hospitals and
surgeons; and other risks and uncertainties more fully described in
NuVasive's press releases and periodic filings with the Securities
and Exchange Commission. NuVasive's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances
arising after the date on which it was made. Contact: Investors:
Michael Lambert Patrick F. Williams EVP & Chief Financial
Officer Vice President, Finance & NuVasive, Inc. Investor
Relations 858-909-1998 NuVasive, Inc. 858-638-5511 Media: Jason
Rando The Ruth Group 646-536-7025 DATASOURCE: NuVasive, Inc.
CONTACT: Michael Lambert, EVP & Chief Financial Officer of
NuVasive, Inc., +1-858-909-1998, , or Investors: Patrick F.
Williams, Vice President, Finance & Investor Relations of
NuVasive, Inc., +1-858-638-5511, ; or Media: Jason Rando of The
Ruth Group, +1-646-536-7025, Web Site: http://www.nuvasive.com/
Copyright